EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy

Chelsey Ortman iD, Rohini Coorg iD, Irfan Ali, Dave Clarke iD, Gloria Diaz-Medina iD, Kimberly Houck iD, Akshat Katyayan iD, Laura Masters, Deepankar Mohanty iD, Anuranjita Nayak iD, Michael Quach, Vijay M Ravindra iD und 12 weitere

Epilepsia · 2025

DOI: 10.1111/epi.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Chelsey Ortman und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurology, Department of Pediatric Neurosciences, Dell Children's Hospital, University of Texas, Austin, Texas, USA. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Drug Resistant Epilepsy, Laser Therapy, Stereotaxic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In children with tuberous sclerosis complex (TSC) and drug‐resistant epilepsy (DRE), magnetic resonance imaging–guided stereotactic laser ablation (SLA) therapy offers less‐invasive treatment compared to craniotomy and resection. Our study seeks to further expand on the long‐term outcomes in patients with TSC‐related DRE who have undergone SLA.

Methods

Patients with TSC and DRE treated with SLA, between July 1, 2016 and January 1, 2022, at our institution were identified retrospectively. Reduction in number of anti‐seizure medications (ASMs), developmental improvement as reported by the patients' families, seizure frequency measured in surgically targeted seizure type and total seizures per day, and Engel classification were evaluated at 6 months, 1 year, 2 years, and thereafter at the most recent follow‐up visit if available.

Results

Forty patients (ages 11 months to 23 years, median age 3.6 years) with TSC underwent SLA. Total follow‐up was on average 2.9 years post‐surgery. Significant (>50%) reduction in total seizure frequency occurred in 80% of patients ( n = 32), with 63% of patients reporting a >90% reduction in seizure frequency ( n = 25) at last follow‐up. Fifty‐eight percent had complete freedom from their surgically targeted seizure type ( n = 23). At last follow up, perceived developmental gains occurred in 63% ( n = 25), reduction in ASM occurred in 40% ( n = 16), and Engel class was III or less in 93% of patients ( n = 37). Significance SLA was safe and effective for most patients, even the very young. A majority of patients achieved improvement in seizure frequency, including the surgically targeted seizure type, but less than half were able to reduce medications. Reported developmental improvement was related to Engel outcomes. Future studies utilizing neuropsychological testing in the full cohort will be required to offer objective insights into post‐operative development profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous SclerosisDrug Resistant EpilepsyLaser TherapyStereotaxic TechniquesHumansChildMaleFemaleAdolescentChild, PreschoolInfantTreatment OutcomeMagnetic Resonance ImagingRetrospective StudiesYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

drug‐resistant epilepsylaser interstitial thermal therapy (LITT)stereotactic laser ablation (SLA)stereo‐electroencephalography (SEEG)tuberous sclerosis complex

Autor:innen und Institutionen

  • Division of Pediatric Neurology, Department of Pediatric Neurosciences, Dell Children's Hospital, University of Texas, Austin, Texas, USA.
  • Division of Neurology and Developmental Neuroscience, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Austin, Texas, USA.
  • Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
  • Department of Radiology, Department of Neuroradiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Psychology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Chelsey Ortman, Rohini Coorg, Dave Clarke, Gloria Diaz-Medina, Kimberly Houck, Akshat Katyayan, Deepankar Mohanty, Anuranjita Nayak, Vijay M Ravindra, James J Riviello, Sonali Sen, Elaine Seto, Danielle Takacs, Cristina Trandafir, John T Freiling, Karen Evankovich, Yingchao Yuan, Kalman A Katlowitz, Anne Anderson

Zitieren

APA

Ortman, C., Coorg, R., Ali, I., Clarke, D., Diaz-Medina, G., Houck, K., Katyayan, A., Masters, L., Mohanty, D., Nayak, A., Quach, M., Ravindra, V. M., Riviello, J. J., Sen, S., Seto, E., Takacs, D., Trandafir, C., Freiling, J. T., Evankovich, K., …, & Anderson, A. (2025). Clinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy. Epilepsia. https://doi.org/10.1111/epi.70036

Vancouver

Ortman C, Coorg R, Ali I, Clarke D, Diaz-Medina G, Houck K, et al. Clinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy. Epilepsia. 2025. doi:10.1111/epi.70036

BibTeX
@article{Ortman2025,
  author = {Ortman, Chelsey and Coorg, Rohini and Ali, Irfan and Clarke, Dave and Diaz-Medina, Gloria and Houck, Kimberly and Katyayan, Akshat and Masters, Laura and Mohanty, Deepankar and Nayak, Anuranjita and Quach, Michael and Ravindra, Vijay M and Riviello, James J and Sen, Sonali and Seto, Elaine and Takacs, Danielle and Trandafir, Cristina and Freiling, John T and Evankovich, Karen and Yuan, Yingchao and Katlowitz, Kalman A and Curry, Daniel and Weiner, Howard L and Anderson, Anne},
  title = {Clinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.70036}
}
Kostenlos starten →